Bone metastasis;L'hyperresorption osseuse au cours des metastases osseuses

Presse Medicale

Volumn 29, Issue 9, 2000, Pages 487-491

  Clezardin Ph ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GROWTH FACTOR; INTEGRIN; PROTEINASE; TRANSFORMING GROWTH FACTOR; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN; PTHLH PROTEIN, HUMAN; TUMOR PROTEIN;

BONE ATROPHY; BONE METASTASIS; CELL INTERACTION; CELL PROLIFERATION; HUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PROTEIN SECRETION; REVIEW; ANIMAL; BONE MARROW; BONE MATRIX; BONE TUMOR; BREAST TUMOR; CELL CULTURE; EXPERIMENTAL NEOPLASM; FEMALE; MELANOMA; METASTASIS; MOUSE; MULTIPLE MYELOMA; OSTEOBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STROMA CELL;

ANIMALS; BONE MARROW; BONE MATRIX; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CYTOKINES; DIPHOSPHONATES; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MELANOMA; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PROTEINS; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 0034635749     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Muncy GR. Mechanisms of bone metastasis. Cancer 1997; 80:1546-56.
2. Baron RE. Anatomy and ultrastructure of bone. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (Favus MJ, editor), Third Edition, Raven Press, 1996, pp 3-10.
3. Strewler GJ, Nissensson RA. Parathyroid hormone-related protein. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (Favus MJ, editor), Second Edition, Raven Press, 1995, pp 61-3.
4. Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfield EM. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Min Res 1996 ; 11:754-9.
5. Pilbeam CC, Harrisson JR, Raisz LC. Prostaglandins and bone metabolism. In: Principles of Bone Biology (Bilezikian JP, Raisz LG and Rodan GA editors), Academic Press, San Diego, 1996, pp 715-28.
6. Manolagas SC, Jilka RL, Bellido T et al. Interleukin-6-type cytokines and their receptors. In: Principles of Bone Biology (Bilezikian JP, Raisz LG and Rodan GA editors), Academic Press, San Diego, 1996, pp 701-13.
7. Pilbeam CC, Harrisson JR, Raisz LG. Prostaglandins and bone metabolism. In: Principles of Bone Biology (Bilezikian JP, Raisz LG and Rodan GA editors), Academic Press, San Diego, 1996, pp 715-28.
8. Akatsu T, Takahashi N, Udagawa N et al. Parathyroid hormone (PTH)-related protein is a potent stimulator of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse marrow cultures. Endocrinology 1989; 125:20-7.
9. Bundred NJ, Ratcliffe WA, Walker RA et al. Parathyroid hormone related protein and hypercalcemia in breast cancer Br Med J 1991 ; 303:1506-9.
10. Powell GJ, Southby J, Danks JA et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991 ; 51:3059-61.
11. Vargas SJ, Gillespie MT, Powell GJ et al. Localization of parathyroid hormone-related protein mRNA expression and metastatic lesions by in situ hybridization. J Bone Min Res 1992 ; 7:971-80.
12. Bouizar Z, Spyratos F, Deytieux S et al. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993 ; 53:5076-8.
13. Bouizar Z, Spyratos F, de Vernejoul MC The parathyroid hormone-related protein (PTHrP) gene: use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis. J Bone Min Res 1999 ; 14:406-14.
14. Kohno N, Kitazawa S, Fukase M et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today 1994 ; 24:215-20.
15. Guise TA, Yin JJ, Taylor SD et al. Evidence for a casual role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996 ; 98:1544-9.
16. Hiraga T, Nakajima T, Ozawa H. Bone resorption induced by a metastatic human melanoma cell line. Bone 1995 ; 16:349-56.
17. Zharg Y, Fujita N, Oh-hara T et al. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene 1998; 16:693-703.
18. Uy HL, Mundy GR, Boyce BF et al. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 1997 ; 57:3194-9.
19. Siwek B, Lacroix M, De Pollak C et al. Secretory products of breast cancer cells specifically affect human osteoblastic cells: partial characterization of active factors. J Bone Min Res 1997; 12:552-60.
20. Clézardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998 ; 54:541-8.
21. 1 into tumor cells. Am J Pathol 1996 ; 148:55-61.
22. 1 integrin stimulate osteoclast formation in vitro. J Bone Min Res 1998; 13:1251-9.
23. Arguello F, Baggs RB, Frantz CN et al. A murine model of experimental metastasis to bone and bone marrow Cancer Res 1988 ; 48:6876-81.
24. Roodman DG. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997 ; 80:1557-63
25. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell 1998 ; 93:165-76.
26. Yasuca H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligard for osteoprotegenn/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998 ; 95:3597-602.
27. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 ; 89:309-19.
28. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitio. Endocrinology 1998 ; 139:1329-37.
29. Akatsu T, Murakami T, Ono K et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998; 23:495-8.
30. Garnero P, Borel O, Byrjalsen I et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998; 273:32347-52.
31. Tezuka K, Nemoto K, Tezuka Y et al. Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J Biol Chem 1994; 269:15006-9.
32. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 1997 ; 15:382-92.
33. Littlewood-Evans A, Bilbe G, Bowler WB et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997 ; 57:5386-90.
34. van der Pluijm G, Vloedgraven H, Papapoulos S et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997 ; 77:665-75.
35. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-4.
36. Bellahcene A, Kroll M, Liebens F et al. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Min Res 1996 ; 11:665-70.
37. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995 ; 146:95-100.
38. Clézardin P, Frappart L, Clerget M, Pechoux C, Delmas P. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993 ; 53:1421-30.
39. Fontana A, Magnetto S, Bruno-Bossio G et al. The expression of thrombospondin-1, a bone matrix protein, in human breast cancer is associated with tumor recurrence including bone metastasis development. Bone 1998 ; 23:T328 (abstract).
40. var der Pluijm G, Vloedgraven HJM, Ivanov B et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 1996 ; 56:1948-55.
41. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. SPARC/Osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998 ; 58:5529-36.
42. Sanchez-Sweatman OH, Lee J, Orr FW, Singh C. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 1997; 13:918-25.
43. Conover CA. The role of insulin-like growth factors and binding proteins in bone cell biology. In: Principles of Bone Biology (Bilezikian JP, Ratsz LG and Rodan GA editors), Academic Press, San Diego, 1996, pp 607-18.
44. Bonewald LF. Transforming growth factor-β. In: Principles of Bone Biology (Bilezikian JP, Raisz LG and Rodan GA editors), Academic Press, San Diego, 1996, pp 647-59.
45. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR and Guise TA. TCF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206
46. Goltzman D. Mechanisms of the development of osteoblastic metastases Cancer 1997 ; 80:1581-7.
47. Mundy GR, DeMartino S, Rowe DW. Collagen and collagen fragments are chemotactic for tumor cells. J Clin Invest 1981; 68: 1102-5.
48. Doerr ME, Jones JI. The role of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells J Biol Chem 1996; 271.2443-7.
49. Ritchie CK, Andrews LR, Thomas KG et al. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997; 138:1145-50.
50. Guise TA, and Mundy GR. Cancer and bone. Endocrine Rev 1998; 19:18-54.
51. Delmas P. Bisphosphonates in the treatment of bone diseases N Engl J Med 1996 ; 335:1836-7.
52. Sasaki A, Alcalde RE, Nishiyama A et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998 ; 58:462-7
53. Yoneda T, Sasaki A, Dunstan C et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibardronate and tissue inhibitor of the matrix matrix metalloproteinase-2. J Clin Invest 1997 ; 99:2509-17.
54. Barinaga M. Designing therapies that target tumor blood vessels. Science 1997 ; 275:482-4.